Neuropsychological and Emotional Functioning in Patients with Cushing’s Syndrome

Table 2

Endocrinological and medical comorbidities.

Pretreatment endocrinological characteristics
ACTH (pg/mL)
Urine free cortisol (mcg/day)
Pretreatment medical comorbidities (number of patients)
Hypertension	12
Diabetes mellitus	9
Sleep apnea	1
Oligomenorrhea	3
Osteoporosis	5
Hypokalemia	2
Hirsutism	4
Heart failure	1
Male hypogonadism	3
Amenorrhea	4
Venous thromboembolic disease	1
Alopecia	1
Endocrine characteristics at the time of testing
Potassium (mEq/L)
Glucose (mg/dL)
Hemoglobin A1c (%)^	6
Posttreatment new secondary conditions
Hypogonadism (, %)	5 (28%)
Treatment at time of testing	20%
Hypothyroidism (, %)	5 (28%)
Treatment at time of testing	100%
Growth hormone deficiency (, %)	2 (11%)
Treatment at time of testing	50%

Mean ACTH levels are based on data from 16 patients, as one patient had missing information due to treatment at different clinic many years prior to the neurocognitive evaluation, while another patient had undetectable ACTH levels (as expected in adrenal Cushing’s). Urine free cortisol levels and pretreatment medical comorbidities are based on data from 17 patients, as the same patient with missing ACTH level did not have the pretreatment information available. ^Mean hemoglobin A1c levels are based on data from 12 patients, while the remaining six patients did not have data available. However, blood glucose levels were reviewed for these patients to confirm that they did not have diabetes mellitus. Data is presented as .